查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1654403

胜肽类抗生素市场规模、份额、趋势分析报告：按疾病、给药途径、产品、分销管道、地区、细分预测，2025-2030 年

Peptide Antibiotics Market Size, Share & Trends Analysis Report By Disease (Skin Infection, HABP/VABP), By Route of Administration (Injectable, Oral), By Product, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

肽类抗生素市场的成长与趋势

根据Grand View Research, Inc.的最新报告，全球胜肽类抗生素市场规模预计到2030年将达到66.4亿美元，2025年至2030年期间的复合年增长率为5.1%。

由于研发活动活性化和胜肽类抗生素领域药物核准数量增加等因素，预计市场将迎来成长机会。此外，预测期内，抗生素抗药性病例的激增以及传统抗生素可能产生的副作用预计也将推动市场的发展。

预计预测期内癌症和其他感染疾病的发生率不断上升将推动成长。例如，根据美国疾病管制与预防中心的数据，2019 年美国报告了 1,752,735 例新癌症病例，同时有 599,589 人死亡。每10万人口中，有439人新发癌症病例，146人死于癌症。此外，根据Globocan 2020的数据，英国2020年新患者457,960例，死亡人数179,648人。最常见的恶性肿瘤类型是乳癌、摄护腺癌和非何杰金氏淋巴瘤。

一些胜肽类抗生素用于治疗癌症，包括非何杰金氏淋巴瘤、何杰金氏淋巴瘤和某些皮肤恶性肿瘤。根据Globocan 2020的数据，非何杰金氏淋巴瘤患者人数为544,352人，何杰金氏淋巴瘤患者人数为83,087人。预计各种现有产品的有效性将因医生的推荐而带来更高的收益。例如，注射用博来霉素 USP 是从链霉菌中分离出来的细胞毒性糖肽抗生素的混合物，用于治疗睪丸癌、鳞状细胞癌和各种淋巴瘤。

此外，预测期内市场参与企业正在进行的产品核可和采取的策略倡议预计（如合作、协作研究、产品发布和业务扩展）将推动市场成长。例如，2021年7月，艾伯维公司宣布，美国FDA核准DALVANCE用于治疗从出生起的儿科患者的急性细菌性皮肤和皮肤结构感染疾病。此外，2020年7月，山德士国际有限公司宣布将向美国市场推出 Cubicin 的学名药——达托霉素注射液 500 毫克，用于治疗患有复杂皮肤和皮肤结构感染疾病以及几种类型血流感染疾病的成年患者。

肽类抗生素市场报告重点

  • 非核醣体合成胜肽抗生素领域占据市场主导地位，占 2024 年全球销售额的 72.79%。
  • 医院药局部门将占据市场主导地位，到 2024 年的市场占有率将达到 43.96%。
  • 由于感染疾病病率上升、患者群众多等因素，预计亚太地区在预测期内将呈现最高的复合年增长率。
  • 北美肽类抗生素市场正在稳步增长，这得益于对抗击医院内获得性细菌性肺炎 (HABP) 和人工呼吸器相关性细菌性肺炎 (VABP) 等复杂感染疾病的有效解决方案的需求不断增长。

目录

第一章调查方法与范围

第 2 章执行摘要

第 3 章胜肽抗生素市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 肽类抗生素市场分析工具
    • 产业分析 – 波特五力分析
    • PESTEL 分析
  • 管道分析

第 4 章胜肽抗生素市场：按产品分類的估计和趋势分析

  • 细分仪表板
  • 全球胜肽类抗生素市场：产品差异分析
  • 产品收益
  • 核醣体合成胜肽抗生素
  • 非核醣体合成胜肽抗生素

第 5 章肽类抗生素市场：按疾病、估计和趋势分析

  • 细分仪表板
  • 全球胜肽类抗生素市场：疾病趋势分析
  • 按疾病和收益
  • 皮肤感染疾病
  • HABP/VABP
  • 血流感染疾病
  • 其他的

6. 胜肽类抗生素市场：依给药途径的估计与趋势分析

  • 细分仪表板
  • 全球胜肽类抗生素市场：给药途径变异分析
  • 按给药途径分類的收益
  • 口服
  • 注射
  • 局部的
  • 其他的

第七章肽类抗生素市场：按分销管道分類的估计和趋势分析

  • 细分仪表板
  • 全球胜肽类抗生素市场：分销管道变化分析
  • 按分销管道分類的收益
  • 医院药房
  • 零售药局
  • 网路药局

第 8 章胜肽类抗生素市场：按产品、疾病、给药途径、通路、地区进行的估计和趋势分析

  • 区域控制面板
  • 2018-2030 年市场规模及预测趋势分析
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第九章 竞争格局

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 供应商概况
    • 2024 年主要企业的市场占有率分析
    • Pfizer Inc.
    • Teva Pharmaceuticals Industries Limited.
    • AbbVie Inc.
    • Merck &Co., Inc.
    • The Menarini Group
    • Sanofi
    • Eli Lilly and Company
    • GSK Plc.
    • NPS Pharmaceuticals
    • Xellia Pharmaceuticals
Product Code: GVR-4-68039-958-4

Peptide Antibiotics Market Growth & Trends:

The global peptide antibiotics market size is estimated to reach USD 6.64 billion by 2030, expanding at a CAGR of 5.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is expected to witness growth opportunities owing to factors such as the increasing research and development activities in field of peptide antibiotics coupled with high number of drug approvals. Moreover, surge in cases of antimicrobial resistance cases and possibility of side effects from the conventional antibiotics are also expected to drive the market during the forecast period.

Increasing prevalence of cancer and other infectious diseases are expected to propel the growth over the forecast period. For instance, according to the CDC, United States reported 1,752,735 new cancer cases along with 599,589 deaths in 2019. For every 100,000 people, 439 new cases were found and 146 people died due to cancer. Further, according to Globocan 2020, U.K. had 457,960 new cases with 179,648 deaths in 2020. The most common types of malignancies were breast, prostate cancer and Non-Hodgkin's lymphoma.

There are some of the peptide antibiotics which are used to treat cancers such as, NHL, Hodgkin's lymphoma, and certain types of skin malignancies. According to Globocan 2020, there were 5,44,352 Non-Hodgkin lymphoma cases and 83,087 Hodgkin's lymphoma cases. The efficiency of various existing products is expected to result into higher revenues owing to doctor recommendations . For instance, BLEOMYCIN for injection USP is the mixture of cytotoxic glycopeptide antibiotics that is isolated from Streptomyces verticillus and is used for the treatment of testicular carcinoma, squamous cell carcinoma, and various types of lymphomas.

Moreover, ongoing product approvals and strategic initiatives undertaken by market players such as partnerships, collaborations, product launches, and expansions are expected to fuel market growth during forecast period. For instance, in July 2021, AbbVie Inc announced that the U.S. FDA approved DALVANCE for the treatment of acute bacterial skin and skin structure infections in pediatric patients from birth. Moreover, in July 2020, Sandoz International GmbH announced introduction of Daptomycin injection 500 mg, a generic version of Cubicin, in the U.S. market for the treatment of adult patients with complicated skin and skin structure infections and several type of bloodstream infections.

Peptide Antibiotics Market Report Highlights:

  • The non-ribosomal synthesized peptide antibiotics segment dominated the market and accounted for 72.79% of the global revenue in 2024.
  • The hospital pharmacies segment dominated the market with a market share of 43.96% in 2024.
  • Asia Pacific region is expected to witness the highest CAGR over the forecast period owing to factors such as, rising prevalence of infectious diseases, and availability of large patient pool
  • The North America peptide antibiotics market is growing steadily, driven by increasing demand for effective solutions to combat complex infections such as hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP).

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Disease
    • 1.2.3. Route of Administration
    • 1.2.4. Distribution channel
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product and disease outlook
    • 2.2.2. Route of administration and distribution channel outlook
  • 2.3. Competitive Insights

Chapter 3. Peptide Antibiotics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. High prevalence of microbial resistance
      • 3.2.1.2. Rising investment in R&D of novel drug
      • 3.2.1.3. Technological advancement in peptide antibiotics
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of treatment
      • 3.2.2.2. Side-effects associated with drug
  • 3.3. Peptide Antibiotics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
  • 3.4. Pipeline Analysis

Chapter 4. Peptide Antibiotics Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Peptide Antibiotics Market: Product Movement Analysis
  • 4.3. Global Peptide Antibiotics Market Estimates and Forecasts, By Product Revenue (USD Million)
  • 4.4. Ribosomal Synthesized Peptide Antibiotics
    • 4.4.1. Ribosomal synthesized peptide antibiotics market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5. Non-ribosomal Synthesized Peptide Antibiotics
    • 4.5.1. Non-ribosomal synthesized peptide antibiotics market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. Peptide Antibiotics Market: Disease Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Peptide Antibiotics Market: Disease Movement Analysis
  • 5.3. Global Peptide Antibiotics Market Estimates and Forecasts, By Disease, Revenue (USD Million)
  • 5.4. Skin Infection
    • 5.4.1. Skin Infection market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5. HABP/VABP
    • 5.5.1. HABP/VABP market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.6. Blood Stream Infections
    • 5.6.1. Blood Stream Infections market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. Peptide Antibiotics Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Peptide Antibiotics Market: Route of Administration Movement Analysis
  • 6.3. Global Peptide Antibiotics Market Estimates and Forecasts, By Route of Administration, Revenue (USD Million)
  • 6.4. Oral
    • 6.4.1. Oral market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5. Injectable
    • 6.5.1. Injectable market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.6. Topical
    • 6.6.1. Topical market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.7. Others
    • 6.7.1. Others market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Peptide Antibiotics Market: Distribution Channel Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global Peptide Antibiotics Market: Distribution Channel Movement Analysis
  • 7.3. Global Peptide Antibiotics Market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
  • 7.4. Hospitals Pharmacies
    • 7.4.1. Hospitals pharmacies market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5. Retail Pharmacies
    • 7.5.1. Retail Pharmacies market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.6. Online Pharmacies
    • 7.6.1. Online Pharmacies market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 8. Peptide Antibiotics Market: Regional Estimates & Trend Analysis By Product, Disease, Route of Administration, and Distribution Channel

  • 8.1. Regional Dashboard
  • 8.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 8.3. North America
    • 8.3.1. U.S.
      • 8.3.1.1. Key country dynamics
      • 8.3.1.2. Regulatory framework/ reimbursement structure
      • 8.3.1.3. Competitive scenario
      • 8.3.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
    • 8.3.2. Canada
      • 8.3.2.1. Key country dynamics
      • 8.3.2.2. Regulatory framework/ reimbursement structure
      • 8.3.2.3. Competitive scenario
      • 8.3.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
    • 8.3.3. Mexico
      • 8.3.3.1. Key country dynamics
      • 8.3.3.2. Regulatory framework/ reimbursement structure
      • 8.3.3.3. Competitive scenario
      • 8.3.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.4. Europe
    • 8.4.1. UK
      • 8.4.1.1. Key country dynamics
      • 8.4.1.2. Regulatory framework/ reimbursement structure
      • 8.4.1.3. Competitive scenario
      • 8.4.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
    • 8.4.2. Germany
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Regulatory framework/ reimbursement structure
      • 8.4.2.3. Competitive scenario
      • 8.4.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
    • 8.4.3. France
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Regulatory framework/ reimbursement structure
      • 8.4.3.3. Competitive scenario
      • 8.4.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
    • 8.4.4. Italy
      • 8.4.4.1. Key country dynamics
      • 8.4.4.2. Regulatory framework/ reimbursement structure
      • 8.4.4.3. Competitive scenario
      • 8.4.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
    • 8.4.5. Spain
      • 8.4.5.1. Key country dynamics
      • 8.4.5.2. Regulatory framework/ reimbursement structure
      • 8.4.5.3. Competitive scenario
      • 8.4.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
    • 8.4.6. Norway
      • 8.4.6.1. Key country dynamics
      • 8.4.6.2. Regulatory framework/ reimbursement structure
      • 8.4.6.3. Competitive scenario
      • 8.4.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
    • 8.4.7. Sweden
      • 8.4.7.1. Key country dynamics
      • 8.4.7.2. Regulatory framework/ reimbursement structure
      • 8.4.7.3. Competitive scenario
      • 8.4.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
    • 8.4.8. Denmark
      • 8.4.8.1. Key country dynamics
      • 8.4.8.2. Regulatory framework/ reimbursement structure
      • 8.4.8.3. Competitive scenario
      • 8.4.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.5. Asia Pacific
    • 8.5.1. Japan
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
    • 8.5.2. China
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
    • 8.5.3. India
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
    • 8.5.4. Australia
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework/ reimbursement structure
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
    • 8.5.5. South Korea
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Regulatory framework/ reimbursement structure
      • 8.5.5.3. Competitive scenario
      • 8.5.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
    • 8.5.6. Thailand
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Regulatory framework/ reimbursement structure
      • 8.5.6.3. Competitive scenario
      • 8.5.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.6. Latin America
    • 8.6.1. Brazil
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
    • 8.6.2. Argentina
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.7. MEA
    • 8.7.1. South Africa
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
    • 8.7.2. Saudi Arabia
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
    • 8.7.3. UAE
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
    • 8.7.4. Kuwait
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. Key company market share analysis, 2024
    • 9.3.2. Pfizer Inc.
      • 9.3.2.1. Company overview
      • 9.3.2.2. Financial performance
      • 9.3.2.3. Product benchmarking
      • 9.3.2.4. Strategic initiatives
    • 9.3.3. Teva Pharmaceuticals Industries Limited.
      • 9.3.3.1. Company overview
      • 9.3.3.2. Financial performance
      • 9.3.3.3. Product benchmarking
      • 9.3.3.4. Strategic initiatives
    • 9.3.4. AbbVie Inc.
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Product benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Merck & Co., Inc.
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Product benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. The Menarini Group
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Product benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. Sanofi
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Product benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Eli Lilly and Company
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Product benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. GSK Plc.
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Product benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. NPS Pharmaceuticals
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Product benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. Xellia Pharmaceuticals
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Product benchmarking
      • 9.3.11.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviations
  • Table 3 List of key distributors
  • Table 4 List of other companies
  • Table 5 List of key emerging company's/technology disruptors/innovators
  • Table 6 North America Peptide Antibiotics Market, By Country, 2018 - 2030 (USD Million)
  • Table 7 North America Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 8 North America Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 9 North America Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 10 North America Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 11 U.S. Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 12 U.S. Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 13 U.S. Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 14 U.S. Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 15 Canada Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 16 Canada Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 17 Canada Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 18 Canada Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 19 Mexico Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 20 Mexico Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 21 Mexico Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 22 Mexico Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 23 Europe Peptide Antibiotics Market, By Country, 2018 - 2030 (USD Million)
  • Table 24 Europe Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 25 Europe Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 26 Europe Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 27 Europe Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 28 U.K. Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 29 U.K. Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 30 UK Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 31 U.K. Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 32 Germany Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 33 Germany Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 34 Germany Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 35 Germany Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 36 France Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 37 France Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 38 France Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 39 France Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 40 Spain Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 41 Spain Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 42 Spain Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 43 Spain Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 44 Italy Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 45 Italy Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 46 Italy Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 47 Italy Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 48 Denmark Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 49 Denmark Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 50 Denmark Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 51 Denmark Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 52 Sweden Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 53 Sweden Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 54 Sweden Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 55 Sweden Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 56 Norway Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 57 Norway Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 58 Norway Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 59 Norway Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 61 Asia Pacific Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 62 Asia Pacific Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 63 Asia Pacific Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 64 Japan Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 65 Japan Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 66 Japan Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 67 Japan Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 68 China Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 69 China Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 70 China Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 71 China Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 72 India Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 73 India Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 74 India Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 75 India Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 76 Australia Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 77 Australia Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 78 Australia Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 79 Australia Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 80 South Korea Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 81 South Korea Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 82 South Korea Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 83 South Korea Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 84 Thailand Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 85 Thailand Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 86 Thailand Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 87 Thailand Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 88 Latin America Peptide Antibiotics Market, By Country, 2018 - 2030 (USD Million)
  • Table 89 Latin America Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 90 Latin America Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 91 Latin America Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 92 Latin America Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 93 Brazil Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 94 Brazil Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 95 Brazil Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 96 Brazil Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 97 Argentina Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 98 Argentina Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 99 Argentina Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 100 Argentina Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 101 MEA Peptide Antibiotics Market, By Country, 2018 - 2030 (USD Million)
  • Table 102 MEA Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 103 MEA Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 104 MEA Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 105 MEA Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 106 South Africa Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 107 South Africa Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 108 South Africa Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 109 South Africa Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 110 Saudi Arabia Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 111 Saudi Arabia Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 112 Saudi Arabia Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 113 Saudi Arabia Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 114 UAE Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 115 UAE Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 116 UAE Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 117 UAE Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 118 Kuwait Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
  • Table 119 Kuwait Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
  • Table 120 Kuwait Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 121 Kuwait Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Peptide antibiotics market Segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Peptide antibiotics market snapshot
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook, revenue, 2024 (USD Million)
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Peptide Antibiotics market driver impact
  • Fig. 14 Peptide antibiotics market restraint impact
  • Fig. 15 SWOT analysis, by factor (political & legal, economic, and technological)
  • Fig. 16 Industry Analysis - Porter's Five Forces
  • Fig. 17 Peptide antibiotics market: Product outlook and key takeaways
  • Fig. 18 Peptide antibiotics market: Product movement analysis & market share 2024 & 2030
  • Fig. 19 Ribosomal synthesized peptide antibiotics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Non-ribosomal synthesized peptide antibiotics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Peptide Antibiotics market: Disease outlook and key takeaways
  • Fig. 22 Peptide Antibiotics market: Disease movement analysis & market share 2024 & 2030
  • Fig. 23 Skin infection market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 HABP/VABP market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Blood stream infections market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Peptide antibiotics market: Route of administration outlook and key takeaways
  • Fig. 28 Peptide antibiotics market: Route of administration movement analysis & market share 2024 & 2030
  • Fig. 29 Oral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Injectable market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Topical market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Peptide antibiotics market: Distribution channel outlook and key takeaways
  • Fig. 34 Peptide antibiotics market: Distribution channel movement analysis & market share 2024 & 2030
  • Fig. 35 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Online pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Global peptide antibiotics market: Regional movement analysis
  • Fig. 39 Global peptide antibiotics market: Regional outlook and key takeaways
  • Fig. 40 Global peptide antibiotics market share and leading players
  • Fig. 41 North America, by country
  • Fig. 42 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 U.S. key country dynamics
  • Fig. 44 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Canada key country dynamics
  • Fig. 46 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Mexico key country dynamics
  • Fig. 48 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 UK key country dynamics
  • Fig. 51 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Germany key country dynamics
  • Fig. 53 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 France key country dynamics
  • Fig. 55 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Italy key country dynamics
  • Fig. 57 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Spain key country dynamics
  • Fig. 59 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Denmark key country dynamics
  • Fig. 61 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Sweden key country dynamics
  • Fig. 63 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Norway key country dynamics
  • Fig. 65 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 China key country dynamics
  • Fig. 68 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Japan key country dynamics
  • Fig. 70 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 India key country dynamics
  • Fig. 72 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Thailand key country dynamics
  • Fig. 74 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 South Korea key country dynamics
  • Fig. 76 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Australia key country dynamics
  • Fig. 78 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Brazil key country dynamics
  • Fig. 81 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Argentina key country dynamics
  • Fig. 83 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 South Africa key country dynamics
  • Fig. 86 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 Saudi Arabia key country dynamics
  • Fig. 88 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 UAE key country dynamics
  • Fig. 90 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Kuwait key country dynamics
  • Fig. 92 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Market share Analysis of key market players, 2024